1305P - ALK rearrangements in non-small cell lung cancer Russian patients

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Pathology/Molecular Biology
Non-small-cell lung cancer
Translational Research
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter Irina Demidova
Citation Annals of Oncology (2014) 25 (suppl_4): iv426-iv470. 10.1093/annonc/mdu349
Authors I. Demidova1, E. Tzepenschikova1, E. Imyanitov2, S. Tjulandin3
  • 1Laboratory Of Molecular Genetic, Moscow city oncology hospital #62, 143423 - Krasnogorsk/RU
  • 2Laboratory Of Molecular Oncology, N.N. Petrov Research Institute of Oncology, 197758 - St. Petersburg/RU
  • 3Clinical Pharmacology And Chemotherapy, N.N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU



Russian Society of Clinical Oncology launched the initiative aimed to improve availability of ALK testing in Russia. The aim of the study is to assess frequency of ALK translocations in Russian Non-Small Cell Lung (NSCLC) patients and to reveal demographic and clinicopathological characteristics of the ALK-positive tumors.


Either FFPE or cytology samples of patients were investigated by FISH (LSI ALK Break Apart probe (Vysis, Abbott), and the results were interpreted using ASCO-CAP Guidelines 2013.


778 EGFR-negative NSCLCs patients were prospectively included from May 2013 to January 2014 (517 men, 261 women; mean age 59 yrs (range: 21 - 91). In 656 (84.4%) cases adenocarcinomas were confirmed; 82 (10.5%), 7 (0.9%), 33 (4,2%) patients had squamous histology, large cell carcinomas and NSCLC NOS, respectively. Evaluation was successful in 722 cases (93%). ALK rearrangements were revealed in 55 (7.6%) patients. Rearrangements were more frequent in adenocarcinoma (7.8%) and in squamous NSCLC (2.5%), but this difference was not statistically significant (р = 0.11). There were few factors significantly associated with high frequency of ALK rearrangements: 1) non-smoking status (13,9% in non-smokers vs. 4% in current/former smokers, р = 0.0001); 2) young age (11.7% in patients younger than 60 years vs. 4.8% in older patients, р = 0.01); 3) female gender, even when adjusted for smoking status and histology (р = 0.05).


Frequency of ALK rearrangements in EGFR mutation-negative lung adenocarcinoma patients is similar to one observed in other European populations. The highest occurrence of ALK translocations is observed in young patients, non-smokers and females.


All authors have declared no conflicts of interest.